We don't know whether the most recent response to this request contains information or not – if you are Megs please sign in and let everyone know.

Discontinuation of Phenelzine Sulphare

Megs made this Official Information request to Pharmaceutical Management Agency

This request has an unknown status. We're waiting for Megs to read recent responses and update the status.

From: Megs

Dear Pharmaceutical Management Agency,

This is an urgent request regarding the discontinuation of Phenelzine (announced 22 April 2020).

The supplier, Link Medical Products, has advised they are unable to continue supplying Phenelzine.

Please provide all information and documentation, including email or other correspondence documents with both internal and external parties, for the following:

1) What other alternative suppliers have been contacted or considered, what was the outcome?

Please provide documentation relating to the attempt to find an alternative suppliers. Australia's supplier has switched from Link Medical to Medsurge who are currently attempting to confirm an ongoing supply of phenelzine for Australians; why is NZ not doing the same?

2) Is the discontinuation of phenelzine related to the current cost of alternatives?

Currently, the only brand available in Australia under the special access scheme is $398+GST for a bottle. Please provide all information and documentation regarding the cost for supply of phenelzine, especially relating to decisions by those within Pharmac.

3) Has phenelzine been permanently discontinued in NZ? Or will it be available when the supply has stabilised?

Please provide anything related to future of phenelzine in NZ.

4) Phenelzine is a last resort for everyone who takes it. Given there are currently 100 people in NZ on it, what sort of risk analysis and discussion has taken place regarding the ongoing management of these New Zealanders?

Please provide all available documentation, including but not limited to reports, briefing, correspondence, transcripts of meetings or phone calls with all internal and external parties, including but not limited to Mental Health Subcommittee of the Pharmacology, Therapeutics Advisory Committee, Department of Health, Local DHBs, MPs. Specifically, I am interested in any estimations around the suicide risk (and management) of these 100 New Zealanders, the potential cost to the health and welfare system given the extremely high likelihood of relapse.

5) Please provide all information related to the suggestion of using tranylcypromine sulphate (Parnate) as "appropriate alternative MAOI for patients", including all reports, correspondence, transcripts, and a list detailing the qualifications and professional experience regarding MAOI and treatment resistant depression of those on the Mental Health Subcommittee of the Pharmacology and Therapeutics Advisory Committee. I would specifically expect to see discussion and acknowledgement from these members that the two MAOI are not interchangeable. Please also include any studies cited or external professionals who were consulted.

I look forward to your response but am greatly disappointed given that on 18 September 2019 Pharmac responded to my OIA request with the following: "In response to your first four questions, the supplier of Nardil and Nardil s29, has advised PHARMAC that it expects to be able to ensure the on-going supply of phenelzine sulphate."

Ngā Mihi,
Megs

Link to this

From: Web Enquiry
Pharmaceutical Management Agency

Thank you for emailing PHARMAC enquiries.

o [1]Read about PHARMAC's response to Coronavirus (COVID-19)
o [2]View a list of all currently funded medicines (the Pharmaceutical
Schedule)
o [3]View the progress of funding applications on the Application
Tracker

We will endeavour to get back to you within five working days.

 

Ngā mihi,

PHARMAC Enquiries

show quoted sections

Link to this

Megs left an annotation ()

Sorry, typo in subject, should be Phenelzine Sulphate (Nardil).

Link to this

danes left an annotation ()

Extremely disheartening news. Nardil (phenelzine) is an extremely effective medication, and, contrary to popular opinion, very safe to administrator over long periods of time. In fact, there is little justification for it not being used as a second, or even first-line treatment.
The suggestion of using tranylcypromine sulphate (Parnate) as "an appropriate alternative MAOI for patients" is unfortunately somewhat misguided. There are significant differences in pharmacological properties between Nardil (a hydrazine) and Parnate (a non-hydazine), most pertinently that Nardil has a potent anti-anxiety effect (GABA) whereas Parnate does not.
Many people can have a profound therapeutic response to Nardil, but unfortunately do not respond to Parnate.
There is a very real possibility that without access to Nardil some patients will commit suicide.
See: https://psychotropical.com/maois/

Link to this

From: Deirdre McCullough
Pharmaceutical Management Agency

Dear Megs,

 

Thank you for your request for official information, received by PHARMAC
on 23 April 2020.

 

Your request has been received and logged. As required under the Official
Information Act 1982, we will respond to your request within 20 working
days. You should receive a response on or before 22 May 2020.

 

If a large amount of information has been requested, we may need to extend
this date (this is provided for in section 15A of the Act). We will advise
you if such an extension is necessary.

 

Our reference number for your request is: OIA 2019-20-158.

 

Regards

 

Deirdre McCullough

 

 

 

Ngā mihi

 

 

Deirdre McCullough | Team Assistant Engagement and Implementation
Directorate

_________________________________________________________________

PHARMAC | Te Pātaka Whaioranga | PO Box 10-254 | Level 9, 40 Mercer
Street, Wellington

DDI: +64 4 483 1046 | P: +64 4 460 4990 | M: +64 (0)21 960 933
|[1]www.pharmac.govt.nz

We are constantly updating our website with information about medicine
supplies and other COVID-19 issues.

See our latest updates at  [2]pharmac.govt.nz/covid19

 

References

Visible links
1. http://www.pharmac.govt.nz/
2. https://www.pharmac.govt.nz/information-...

Link to this

From: Web Enquiry
Pharmaceutical Management Agency


Attachment 2019 20 158 Extension of Response.pdf
93K Download View as HTML


Good morning Meg

Attached is correspondence in relation to your recent OIA request.

Kind regards, Susan

Susan Robertson I Government Services Policy Adviser I Policy Team
PHARMAC | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington
DDI: +64 4 830 6201 | P: +64 4 460 4990 | M: +64 021 846 800 www.pharmac.govt.nz
We are constantly updating our website with information about medicine supplies and other COVID-19 issues. See our latest updates at pharmac.govt.nz/covid19

Link to this

We don't know whether the most recent response to this request contains information or not – if you are Megs please sign in and let everyone know.

Things to do with this request

Anyone:
Pharmaceutical Management Agency only: